The MHRA says Dermaved is recalling this product from patients due to presence of clobetasol propionate (0.001% w/w).

Clinical trial evidence shows that people who have ponesimod have fewer relapses than people who have teriflunomide., according to NICE final draft guidance.

The updates include a new recommendation on PSA thresholds for the referral of suspected urological cancer. They also cover the staging of prostate cancer.